OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	55
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	29
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	23
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	21
Learning pharmacometric covariate model structures with symbolic regression networks	19
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	19
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	18
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	14
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	14
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	13
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	13
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	13
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	12
ADPO: automatic-differentiation-assisted parametric optimization	12
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Current practices for QSP model assessment: an IQ consortium survey	11
Imputation of missing clock times – application to procalcitonin concentration time course after birth	11
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	10
Informatics for toxicokinetics	10
Training the next generation of pharmacometric modelers: a multisector perspective	10
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	10
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	9

Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	9
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	9
Thanks to our Reviewers of 2022!	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	8
Scoping review of the role of pharmacometrics in model-informed drug development	8
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	6
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	6
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	5
Application of machine learning based methods in exposure–response analysis	5
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	5
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	5
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	5
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	5